Law360, New York (August 27, 2012, 8:44 PM ET) -- A New Jersey federal judge ruled last week that a woman's doctor would have prescribed her a Baxter Healthcare Corp. drug even if a warning label described its clotting risks in more detail, handing drugmakers an important victory in an undeveloped area of law in the pharma-heavy state, attorneys say.
Plaintiff Evageline Baker received Baxter-made heparin, an anti-clotting drug, as part of treatment for a triple coronary bypass. She soon developed heparin-induced thrombocytopenia and thrombosis, or HITT, suffering blood clots and gangrene in one of her...
Baxter Win Gives Drugmakers A Leg Up In NJ Warning Suits
To view the full article, take a free trial now.
